Reviewing Pieris Pharmaceuticals (PIRS) and Exelixis (EXEL)

Pieris Pharmaceuticals (NASDAQ: PIRS) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Volatility & Risk

Pieris Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.

Earnings & Valuation

This table compares Pieris Pharmaceuticals and Exelixis’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pieris Pharmaceuticals $25.27 million 13.70 -$17.64 million ($0.40) -16.08
Exelixis $452.48 million 13.89 $154.22 million $0.51 41.55

Exelixis has higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.


This table compares Pieris Pharmaceuticals and Exelixis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -69.82% -162.54% -19.05%
Exelixis 34.08% 81.05% 27.10%

Insider and Institutional Ownership

44.0% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.5% of Exelixis shares are owned by institutional investors. 4.1% of Pieris Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pieris Pharmaceuticals and Exelixis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 5 0 3.00
Exelixis 0 3 9 0 2.75

Pieris Pharmaceuticals presently has a consensus target price of $11.50, indicating a potential upside of 78.85%. Exelixis has a consensus target price of $34.00, indicating a potential upside of 60.45%. Given Pieris Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Pieris Pharmaceuticals is more favorable than Exelixis.


Exelixis beats Pieris Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company’s CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company’s XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply